BioCentury | Apr 15, 2013
Company News

National Patent Development Corp., PolyMasc deal

...NPD’s Hydro Med Sciences division (New Brunswick, N.J.) and PolyMASC extended their June 1996 agreement, in which...
...New Brunswick, N.J.) and PolyMASC extended their June 1996 agreement, in which they are applying Hydro Med’s...
BioCentury | Mar 21, 2005
Finance

Ebb & Flow

...up to $74.8 million through UBS; Banc of America; First Albany; and Fortis. Valera (formerly Hydro Med...
BioCentury | Mar 15, 2005
Financial News

Valera files for IPO

...the palliative treatment of advanced prostate cancer. The company changed its name to Valera from Hydro Med...
BioCentury | Aug 23, 2004
Finance

Follow the money

...Oakwood Medical Investors; Palo Alto Investors; S.R. One; Sprout Group; and William Blair. Valera (formerly Hydro Med...
BioCentury | Aug 20, 2004
Financial News

Valera raises $11.5 million

...LHRH ) hydrogel implant for the palliative treatment of metastatic prostate cancer. Valera (formerly Hydro Med...
BioCentury | Oct 7, 2002
Company News

Hydro Med, Paladin sales and marketing update

...Basingstoke, U.K.) gave back certain rights for the product to Hydro (see BioCentury, Jan. 7). Hydro Med Sciences Inc....
BioCentury | Sep 23, 2002
Clinical News

Histrelin hydrogel implant: Phase I/II

...Histrelin in patients with CPP, a disorder involving early onset of sexual development in preadolescents. Hydro Med Sciences Inc....
...Receptor agonist Target: Luteinizing hormone-releasing hormone (LHRH) Description: Synthetic nonapeptide agonist of LHRH delivered using Hydro Med's...
BioCentury | Jul 15, 2002
Clinical News

Histrelin hydrogel implant: The company completed enrollment in an open-label U.S. Phase III trial of its Histrelin long-acting LHRH hydrogel implant in a total

Hydro Med Sciences Inc. , Cranbury, N.J. Product: Histrelin hydrogel implant Business: Cancer Therapeutic category: Receptor agonist Target: Luteinizing hormone-releasing hormone (LHRH) Description: Synthetic nonapeptide agonist of LHRH Indication: Treat metastatic prostate cancer Endpoint: Hormonally castrate...
BioCentury | Jul 10, 2002
Clinical News

Hydro completes Phase III prostate cancer enrollment

Hydro Med (Cranbury, N.J.) completed enrollment in a Phase III trial of its Histrelin long-acting LHRH hydrogel implant to treat prostate cancer. In January, Shire (LSE:SHP; SHPGY) gave back certain rights for the product to...
BioCentury | Dec 27, 2001
Company News

Shire, HydroMed amend Histrelin deal

...licensing deal for HydroMed's Histrelin long-acting LHRH hydrogel implant to treat prostate cancer. As amended, Hydro Med...
Items per page:
1 - 10 of 12
BioCentury | Apr 15, 2013
Company News

National Patent Development Corp., PolyMasc deal

...NPD’s Hydro Med Sciences division (New Brunswick, N.J.) and PolyMASC extended their June 1996 agreement, in which...
...New Brunswick, N.J.) and PolyMASC extended their June 1996 agreement, in which they are applying Hydro Med’s...
BioCentury | Mar 21, 2005
Finance

Ebb & Flow

...up to $74.8 million through UBS; Banc of America; First Albany; and Fortis. Valera (formerly Hydro Med...
BioCentury | Mar 15, 2005
Financial News

Valera files for IPO

...the palliative treatment of advanced prostate cancer. The company changed its name to Valera from Hydro Med...
BioCentury | Aug 23, 2004
Finance

Follow the money

...Oakwood Medical Investors; Palo Alto Investors; S.R. One; Sprout Group; and William Blair. Valera (formerly Hydro Med...
BioCentury | Aug 20, 2004
Financial News

Valera raises $11.5 million

...LHRH ) hydrogel implant for the palliative treatment of metastatic prostate cancer. Valera (formerly Hydro Med...
BioCentury | Oct 7, 2002
Company News

Hydro Med, Paladin sales and marketing update

...Basingstoke, U.K.) gave back certain rights for the product to Hydro (see BioCentury, Jan. 7). Hydro Med Sciences Inc....
BioCentury | Sep 23, 2002
Clinical News

Histrelin hydrogel implant: Phase I/II

...Histrelin in patients with CPP, a disorder involving early onset of sexual development in preadolescents. Hydro Med Sciences Inc....
...Receptor agonist Target: Luteinizing hormone-releasing hormone (LHRH) Description: Synthetic nonapeptide agonist of LHRH delivered using Hydro Med's...
BioCentury | Jul 15, 2002
Clinical News

Histrelin hydrogel implant: The company completed enrollment in an open-label U.S. Phase III trial of its Histrelin long-acting LHRH hydrogel implant in a total

Hydro Med Sciences Inc. , Cranbury, N.J. Product: Histrelin hydrogel implant Business: Cancer Therapeutic category: Receptor agonist Target: Luteinizing hormone-releasing hormone (LHRH) Description: Synthetic nonapeptide agonist of LHRH Indication: Treat metastatic prostate cancer Endpoint: Hormonally castrate...
BioCentury | Jul 10, 2002
Clinical News

Hydro completes Phase III prostate cancer enrollment

Hydro Med (Cranbury, N.J.) completed enrollment in a Phase III trial of its Histrelin long-acting LHRH hydrogel implant to treat prostate cancer. In January, Shire (LSE:SHP; SHPGY) gave back certain rights for the product to...
BioCentury | Dec 27, 2001
Company News

Shire, HydroMed amend Histrelin deal

...licensing deal for HydroMed's Histrelin long-acting LHRH hydrogel implant to treat prostate cancer. As amended, Hydro Med...
Items per page:
1 - 10 of 12